Daneschvar Homayoun L, Aronson Mark D, Smetana Gerald W
Harvard Medical School, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Mass.
Harvard Medical School, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Mass.
Am J Med. 2016 Aug;129(8):879.e1-6. doi: 10.1016/j.amjmed.2016.02.009. Epub 2016 Mar 4.
Obesity is a growing health problem in our society and its treatment has been challenging. In recent decades, several anti-obesity drugs have been withdrawn from the market because of reported and documented adverse effects. After years of interruption, the US Food and Drug Administration (FDA) has recently approved multiple new anti-obesity drugs. The majority of these medications are taken orally, and only one is administered subcutaneously. In this article, we review the efficacy, adverse effects, and mechanism of action of all 5 FDA-approved drugs.
肥胖在我们的社会中是一个日益严重的健康问题，其治疗一直具有挑战性。近几十年来，几种抗肥胖药物因报告的和记录在案的不良反应而被撤出市场。经过数年的中断后，美国食品药品监督管理局（FDA）最近批准了多种新型抗肥胖药物。这些药物大多数为口服给药，只有一种为皮下注射给药。在本文中，我们综述了FDA批准的所有5种药物的疗效、不良反应及作用机制。
